Burosumab

證據等級: L5

預測適應症: 10 個

Burosumab: From X-linked Hypophosphatemia to Renal Osteodystrophy

One-Sentence Summary

Burosumab (Crysvita®) is a fully human anti-FGF23 monoclonal antibody approved internationally for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO), but not yet registered in Singapore. The TxGNN model predicts it may be effective for Renal Osteodystrophy — a metabolic bone disorder complicating chronic kidney disease — with 0 clinical trials and 1 review publication directly supporting this direction.

⚠️ Critical Interpretation Note: Renal osteodystrophy ranks #1 by TxGNN prediction score (96.93%), but this reflects AI network topology rather than clinical evidence priority. The strongest clinical evidence belongs to bone remodeling disease (rank #4, L1), which is backed by 2 completed Phase 3 RCTs and represents burosumab's actual regulatory approval basis. The score ranking should not be read as a clinical readiness ranking.

Quick Overview

Item	Content
Original Indication	X-linked hypophosphatemia (XLH); Tumor-induced osteomalacia (TIO)
Predicted New Indication	Renal Osteodystrophy
TxGNN Prediction Score	96.93%
Evidence Level	L4 (for renal osteodystrophy)
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available from local regulatory sources. Based on published information, burosumab is a fully human IgG1 monoclonal antibody that binds to and inhibits fibroblast growth factor 23 (FGF23). In X-linked hypophosphatemia, loss-of-function mutations in the PHEX gene cause excess circulating FGF23, which suppresses renal tubular phosphate reabsorption and reduces 1,25-dihydroxyvitamin D₃ synthesis. The result is chronic hypophosphatemia and defective bone mineralization (osteomalacia/rickets). By neutralizing FGF23, burosumab restores phosphate homeostasis and corrects skeletal mineralization — a mechanism that has been validated in two Phase 3 RCTs and underpins its FDA and EMA approvals.

Renal osteodystrophy (ROD) is a complex spectrum of bone pathology arising in chronic kidney disease (CKD), driven by interrelated disturbances: phosphate retention, reduced 1,25(OH)₂D₃ synthesis, secondary hyperparathyroidism, and defective bone mineralization. The FGF23–KLOTHO axis is central to ROD pathophysiology — FGF23 rises early in CKD as the body attempts to compensate for phosphate overload. This draws a mechanistic parallel to XLH, where FGF23 is also the primary driver of mineral dysregulation, and gives TxGNN a plausible topological basis for predicting burosumab efficacy in ROD.

However, this parallel is mechanistically double-edged and clinically hazardous without further study. In XLH, FGF23 is inappropriately elevated and pathological; in CKD, FGF23 elevation is a compensatory response. Blocking FGF23 in the CKD context may paradoxically worsen hyperphosphatemia — a leading driver of vascular calcification and cardiovascular mortality in this population. Until prospective studies directly address this safety-efficacy trade-off, renal osteodystrophy must remain a research question rather than an actionable repurposing target.

Clinical Trial Evidence

Currently no related clinical trials registered for renal osteodystrophy.

Supplementary: Bone Remodeling Disease (Rank #4) — Strongest Evidence Cluster

Although renal osteodystrophy is TxGNN's top-scored prediction, bone remodeling disease (score 95.49%, Evidence Level L1) carries by far the strongest clinical evidence, including the pivotal Phase 3 trials that secured burosumab's global regulatory approvals. This section is included to provide a complete picture of where the evidence actually stands.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02526160	Phase 3	Completed	134	Pivotal randomized double-blind placebo-controlled trial in adults with XLH. Demonstrated significant serum phosphorus normalization and bone biopsy-confirmed improvement in mineralization lag time — the primary evidence supporting FDA and EMA approval of burosumab
NCT02537431	Phase 3	Completed	14	Open-label single-arm trial evaluating burosumab (KRN23) in adults with XLH-associated osteomalacia. Primary endpoint: improvement in osteoid volume/bone volume (OV/BV) on bone biopsy — directly supported the TIO indication approval
NCT03993821	Early Phase 1	Unknown	1	Single-patient trial in Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS). Proof-of-concept signal only; status unknown and evidence weight negligible

Also identified for Impaired Renal Function (Rank #2):

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06921720	NA	Not Yet Recruiting	65	³¹P-MRS spectroscopy study measuring ATP concentration in phosphate diabetes (XLH and acquired causes). Diagnostic/biomarker design — not a burosumab intervention trial, but relevant to phosphate metabolism background in renal disease

Literature Evidence

For Renal Osteodystrophy (Rank #1, Primary Prediction)

PMID	Year	Type	Journal	Key Findings
37927073	2024	Review	Current Pediatric Reviews	Reviews diagnosis and management of hypophosphatasia and XLH in children; highlights diagnostic delays, complex calcium-phosphate pathophysiology, and emerging treatments — does not directly assess burosumab in ROD but provides mechanistic background

For Bone Remodeling Disease (Rank #4, Strongest Evidence)

PMID	Year	Type	Journal	Key Findings
37180412	2022	Narrative Review	Therapeutic Advances in Rare Disease	Comprehensively reviews burosumab benefits versus conventional therapy in adult XLH; covers improvement in bone pain, osteomalacia healing, enthesopathies, fracture repair, and quality of life — strongest review-level evidence for FGF23 blockade in bone disease
37843399	2024	Cohort/Observational	J Clin Endocrinol Metab	Reassuring cardiovascular data in adults with XLH on conventional therapy; contextualizes long-term safety monitoring needs given elevated FGF23 and cardiovascular risk associations
35235937	2023	Review	Hormone Research in Paediatrics	Updates pediatric bone disease treatment landscape including burosumab for XLH and novel agents for osteoporosis and achondroplasia

For Impaired Renal Function (Rank #2)

PMID	Year	Type	Journal	Key Findings
38195892	2024	Case Report	Calcified Tissue International	Key case: Successful burosumab treatment in a 61-year-old male with XLH and CKD Stage 3b. Phosphate normalization was achieved despite renal impairment. Establishes proof-of-concept but also highlights that this remains off-label and unstudied in formal trials
32701599	2020	Review/Perspective	Current Opinion in Nephrology and Hypertension	Reviews burosumab mechanism in XLH and discusses FGF23's role in CKD-MBD; explicitly identifies CKD as a candidate population for FGF23 blockade research, with cautions
36382755	2022	Review	Archives of Endocrinology and Metabolism	Reviews FGF23-driven hypophosphatemic disorders (XLH, oncogenic osteomalacia) and treatment advances; provides mechanistic framework linking phosphate regulation to renal function
35103802	2022	Review	Zeitschrift fur Rheumatologie	Reviews tumor localization and management of tumor-induced osteomalacia (TIO) — FGF23-driven phosphate-wasting syndrome directly treated by burosumab; contextualizes FGF23 blockade across different disease etiologies
31905439	2019	Review	Annals of Pediatric Endocrinology & Metabolism	Foundational review of skeletal mineralization mechanisms; explains how calcium and phosphate deficiency impair hydroxyapatite crystal formation — underpins rationale for phosphate restoration therapy

Singapore Market Information

Burosumab (Crysvita®) is not registered with the Health Sciences Authority (HSA) of Singapore. No product licenses are on record, and the drug is currently not commercially available in Singapore through standard channels.

Internationally, burosumab has received approval from the U.S. FDA (April 2018), the European Medicines Agency (February 2018), and regulators in Japan, Canada, and other jurisdictions — for X-linked hypophosphatemia in adults and pediatric patients aged ≥1 year, and for tumor-induced osteomalacia (TIO) in adults. Singapore patients seeking access would currently require individual compassionate use or special access applications.

Safety Considerations

Please refer to the Crysvita® international prescribing information (FDA label or EMA SmPC) for complete safety information, as no Singapore HSA product labeling is available.

Population-specific safety signal for CKD: The mechanistic rationale for repurposing to renal osteodystrophy identifies a critical safety concern — FGF23 inhibition in CKD may worsen hyperphosphatemia and accelerate vascular calcification. Any clinical investigation in this population must include rigorous serum phosphate monitoring, vascular calcification assessment, and predefined stopping rules.

Hypocalcemic Rickets (Rank #9) — Contraindication Signal: Burosumab should not be considered for hypocalcemic rickets (e.g., vitamin D deficiency, VDDR). The mechanistic basis is opposite: blocking FGF23 in a patient without FGF23 excess is not therapeutic and may impair 1,25(OH)₂D₃ synthesis, potentially worsening hypocalcemia. This is flagged as a contraindication signal in the prediction analysis.

Conclusion and Next Steps

Primary Recommendation (Renal Osteodystrophy, Rank #1)

Decision: Hold

Rationale: Despite the highest TxGNN prediction score (96.93%), renal osteodystrophy has only L4 evidence — a single background review with no clinical trials. The mechanistic rationale is theoretically plausible but carries an inherent safety risk of worsening hyperphosphatemia in CKD, making premature advancement inappropriate.

Secondary Recommendation (Bone Remodeling Disease, Rank #4)

Decision: Proceed with Guardrails

Rationale: Two completed Phase 3 RCTs (NCT02526160, NCT02537431) directly demonstrate burosumab efficacy in FGF23-driven bone mineralization disorders — the highest evidence level (L1) in this dataset. This evidence base is the foundation of burosumab's existing global approvals for XLH and TIO, and supports expansion to related FGF23-driven bone remodeling indications.

To proceed, the following is needed:

Singapore HSA registration: Initiate a submission for the existing XLH/TIO indications as the regulatory foundation; currently no local approval exists
MOA documentation (DG002): Retrieve full mechanism of action data from DrugBank API to strengthen mechanistic analysis sections
Safety data (DG001): Download and parse Crysvita® package insert PDF (from FDA or EMA sources) to populate key warnings, contraindications, and drug interaction data
CKD safety study design: For the renal osteodystrophy research question, develop a dedicated Phase 1/2 protocol with serial serum phosphate, PTH, FGF23, and vascular calcification scoring at minimum 6-month intervals
Renal dosing investigation: Current burosumab dosing is validated only in patients with normal-to-mildly impaired renal function; formal pharmacokinetic studies in CKD Stage 3b–4 patients are required before any expanded use
Orphan drug pathway assessment: Evaluate Singapore's orphan drug incentive framework for any new indication submissions given the rare disease context
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.